Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients

Authors: B. Cvetković, V. Vučić, Z. Cvetković, T. Popović, M. Glibetić

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

The relationship between plasma levels of total phospholipids (PL) and/or PL fractions and neoplastic diseases are not fully understood. Therefore, the aim of this study was to analyze concentrations and distribution of plasma phospholipids in patients with prostate cancer (PCa) related to the Gleason score, clinical stage and pathologic grade of prostate cancer. We analyzed plasma phospholipids in 57 newly diagnosed, untreated PCa patients and in 43 age-matched healthy male subjects. Significantly lower (P < 0.01) levels of total plasma PL and all PL classes were found in PCa patients when compared with healthy subjects. The relative concentrations of PL fractions were also changed. Further decrease of total PL and PL fractions was found related to an increase of clinical stadium, pathologic grade, and Gleason score, with phosphatidylethanolamine as the most sensitive plasma PL, the level of which significantly decreased even at the first stage of PCa. Our results showed an altered plasma PL profile in PCa patients, which may contribute to monitoring of the disease progression.
Literature
1.
Wright MM, Howe AG, Zaremberg V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem Cell Biol. 2004;82(1):18–26.PubMedCrossRef
2.
Wolf C, Quinn PJ. Lipidomics: practical aspects and applications. Prog Lipid Res. 2008;47(1):15–36.PubMedCrossRef
3.
Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26:1015–35.PubMed
4.
Tepsic J, Vucic V, Arsic A, Blazencic-Mladenovic V, Mazic S, Glibetic M. Plasma and erythrocyte phospholipid fatty acid profile in professional basketball and football players. Eur J Appl Physiol. 2009;107(3):359–65.PubMedCrossRef
5.
Kim H, Min HK, Kong G, Moon MH. Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem. 2009;393(6–7):1649–56.PubMedCrossRef
6.
Min HK, Kong G, Moon MH. Quantitative analysis of urinary phospholipids found in patients with breast cancer by nanoflow liquid chromatography-tandem mass spectrometry: II. Negative ion mode analysis of four phospholipid classes. Anal Bioanal Chem. 2010;396(3):1273–80.PubMedCrossRef
7.
Preetha A, Banerjee R, Huilgol N. Surface activity, lipid profiles and their implications in cervical cancer. J Cancer Res Ther. 2005;1(3):180–6.PubMedCrossRef
8.
Cvetkovic Z, Cvetkovic B, Petrovic M, et al. Lipid profile as a prognostic factor in cancer patients. J BUON. 2009;14(3):501–6.PubMed
9.
Sullentrop F, Moka D, Neubauer S, et al. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002;15(1):60–8.PubMedCrossRef
10.
Taylor LA, Arends J, Hodina AK, Unger C, Massing U. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007;6:17.PubMedCrossRef
11.
Kuliszkiewicz-Janus M, Janus W, Baczynski S. Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 1996;161(3B):1587–94.
12.
Raffelt K, Moka D, Sullentrop F, Dietlein M, Hahn J, Schicha H. Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in vitro (31)P high-resolution NMR study. NMR Biomed. 2000;13(1):8–13.PubMedCrossRef
13.
Grubb RL 3rd, Kibel AS. Prostate cancer: screening, diagnosis and management in 2007. Mo Med. 2007;104(5):408–13. quiz 413–414.PubMed
14.
Vucic V, Niciforovic A, Adzic M, Radojcic MB, Ruzdijic S. The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells. Invest New Drugs. 2008;26(4):309–17.PubMedCrossRef
15.
Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal. 2010;10:1919–31.PubMedCrossRef
16.
Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol. 2004;28(7):946–52.PubMedCrossRef
17.
Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989;141(5):1088–90.PubMed
18.
Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.PubMed
19.
American Joint Committee on Cancer (AJCC), et al. Prostate. In: Greene FL, Pge DL, Fleming ID, Fritz AG, Balch CM, editors. AJCC cancer staging manual, vol. 6. New York (NY): Springer; 2002. p. 309–16.
20.
Marinovic V, Nedic O, Stanojevic N, Baricevic I, Pavlica S. Investigation of the relationship between two major prostate tumour markers. Yugoslav Med Biochem. 2000;19(4):407–10.
21.
Zilversmit DB, Davis AK. Microdetermination of plasma phospholipids by trichloroacetic acid precipitation. J Lab Clin Med. 1950;35(1):155–60.PubMed
22.
Ristic V, Tepsic V, Ristic-Medic D, et al. Plasma and erythrocyte phospholipid fatty acids composition in Serbian hemodialyzed patients. Ren Fail. 2006;28(3):211–6.PubMedCrossRef
23.
Marinetti GV, Albrecht M, Ford T, Stotz E. Analysis of human plasma phosphatides by paper chromatography. Biochim Biophys Acta. 1959;36:4–13.PubMedCrossRef
24.
Khuu Thi-Dinh KL, Demarne Y, Nicolas C, Lhuillery C. Effect of dietary fat on phospholipid class distribution and fatty acid composition in rat fat cell plasma membrane. Lipids. 1990;25(5):278–83.PubMedCrossRef
25.
Zeghari N, Younsi M, Meyer L, Donner M, Drouin P, Ziegler O. Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia: a study in nondiabetic and diabetic obese women. Int J Obes Relat Metab Disord. 2000;24(12):1600–7.PubMedCrossRef
26.
Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599–603.PubMed
27.
Kuliszkiewicz-Janus M, Baczynski S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn Reson Med. 1996;35(4):449–56.PubMedCrossRef
28.
Kuliszkiewicz-Janus M, Baczynski S. Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim Biophys Acta. 1997;1360(1):71–83.PubMed
29.
Cvetkovic Z, Vucic V, Cvetkovic B, et al. Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol. 2010;89(8):775–82.PubMedCrossRef
30.
Murphy RA, Wilke MS, Perrine M, et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin Nutr. 2010;29(4):482–7.PubMedCrossRef
31.
Marra CA, de Alaniz MJ. Regulatory effect of various steroid hormones on the incorporation and metabolism of [14C]stearate in rat hepatoma cells in culture. Mol Cell Biochem. 1995;145(1):1–9.PubMedCrossRef
32.
Koo JM, Shim BS. Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml. Korean J Urol. 2010;51(12):831–5.PubMedCrossRef
33.
Morote J, Planas J, Ramirez C, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010;105(4):481–4.PubMedCrossRef
34.
Zhao Z, Xiao Y, Elson P, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007;25(19):2696–701.PubMedCrossRef
Metadata
Title
Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients
Authors
B. Cvetković
V. Vučić
Z. Cvetković
T. Popović
M. Glibetić
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9914-z

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue

Case Report

Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer

Original Paper

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer

Original Paper

Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples

Letter to the Editor

Primary sarcomatoid malignant mesothelioma of the pericardium

Original Paper

The major stressful life events and cancer: stress history and cancer

Original Paper

Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits